You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameKetorolac
Accession NumberDB00465  (APRD01060)
TypeSmall Molecule
GroupsApproved
DescriptionA pyrrolizine carboxylic acid derivative structurally related to indomethacin. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
Structure
Thumb
Synonyms
(+-)-5-Benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
(+-)-Ketorolac
Ketorolac
Kétorolac
Ketorolaco
Ketorolacum
rac-Ketorolac
External Identifiers
  • BPPC
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AcularSolution / drops5 mg/mLOphthalmicAllergan, Inc.1992-12-01Not applicableUs
AcularSolution5 mg/mLOphthalmicRebel Distributors Corp.1992-11-09Not applicableUs
AcularSolution / drops5 mg/mLOphthalmicSTAT Rx USA LLC1992-12-01Not applicableUs
Acular Liq 0.5%Solution0.5 %OphthalmicAllergan Inc1992-12-31Not applicableCanada
Acular LsSolution0.4 %OphthalmicAllergan Inc2004-03-08Not applicableCanada
Acular LsSolution / drops4 mg/mLOphthalmicAllergan, Inc.2003-08-19Not applicableUs
AcuvailSolution0.45 %OphthalmicAllergan Inc2012-01-10Not applicableCanada
AcuvailSolution / drops4.5 mg/mLOphthalmicAllergan, Inc.2009-08-01Not applicableUs
KetorolacTablet10 mgOralAa Pharma Inc1998-07-03Not applicableCanada
KetorolacSolution0.5 %OphthalmicAa Pharma Inc2002-12-06Not applicableCanada
Ketorolac TromethamineSolution / drops4 mg/mLOphthalmicPhysicians Total Care, Inc.2014-03-28Not applicableUs
Ketorolac TromethamineSolution / drops4 mg/mLOphthalmicPacific Pharma, Inc.2013-11-21Not applicableUs
Ketorolac Tromethamine Injection USPLiquid30 mgIntramuscularSandoz Canada Incorporated1999-05-21Not applicableCanada
Ketorolac Tromethamine Injection USPLiquid10 mgIntramuscularSabex IncNot applicableNot applicableCanada
Ketorolac Tromethamine Injection, USPLiquid30 mgIntramuscularFresenius Kabi Canada Ltd2002-05-23Not applicableCanada
Ketorolac Tromethamine Injection, USPSolution30 mgIntramuscularHospira Healthcare Corporation2014-05-29Not applicableCanada
Ketorolac Tromethamine Injection, USPSolution30 mgIntramuscularMda Inc.2016-04-26Not applicableCanada
Novo-ketorolac - Tab 10mgTablet10 mgOralNovopharm Limited1998-06-022015-10-26Canada
Nu-ketorolacTablet10 mgOralNu Pharm Inc1998-10-202012-09-04Canada
Nu-ketorolac Ophthalmic SolutionSolution0.5 %OphthalmicNu Pharm IncNot applicableNot applicableCanada
Ratio-ketorolacSolution0.5 %OphthalmicRatiopharm Inc Division Of Teva Canada Limited2003-07-142014-09-19Canada
Riva-ketorolac 10 mgTablet10 mgOralLaboratoire Riva IncNot applicableNot applicableCanada
SprixSpray, metered15.75 mg/1NasalEgalet Us Inc.2011-04-26Not applicableUs
SprixSpray, metered15.75 mg/1NasalMedsource Pharmaceuticals2011-04-262016-02-25Us
SprixSpray, metered15.75 mg/1NasalH.J. Harkins Company, Inc.2011-04-26Not applicableUs
SprixSpray, metered15.75 mg/1NasalAmerican Regent, Inc.2011-04-262016-01-16Us
SprixSpray, metered15.75 mg/1NasalPhysicians Total Care, Inc.2011-07-20Not applicableUs
ToradolTablet10 mgOralAtnahs Pharma Uk Limited1995-12-31Not applicableCanada
Toradol ImSolution10 mgIntramuscularAtnahs Pharma Uk Limited1996-10-16Not applicableCanada
Toradol Im 30mg/mlLiquid30 mgIntramuscularHoffmann La Roche Limited1996-12-312011-01-04Canada
Toradol Inj 10mg/mlLiquid10 mgIntramuscularSyntex Inc.1993-12-311997-08-26Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ketorolac InjectableSolution30 mgIntramuscularApotex Inc2001-12-04Not applicableCanada
KetorolacTablet, film coated10 mg/1OralSTAT Rx USA LLC2010-09-15Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralKeltman Pharmaceuticals Inc.2010-04-20Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicAkorn Inc.2009-11-05Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicLake Erie Medical DBA Quality Care Products LLC2009-11-05Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousAmphastar Pharmaceuticals, Inc.2016-03-11Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralTeva Pharmaceuticals Usa, Inc.1998-06-17Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2004-07-21Not applicableUs
Ketorolac TromethamineSolution5 mg/1OphthalmicREMEDYREPACK INC.2013-04-15Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousWockhardt Limited2007-03-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralDIRECT RX2014-01-01Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicProficient Rx LP2009-11-05Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousRebel Distributors Corp1999-01-27Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousREMEDYREPACK INC.2014-10-10Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousA S Medication Solutions2005-04-28Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousREMEDYREPACK INC.2016-11-14Not applicableUs
Ketorolac TromethamineInjection15 mg/mLIntramuscular; IntravenousPfizer Laboratories Div Pfizer Inc2011-05-112016-04-13Us
Ketorolac TromethamineSolution / drops5 mg/mLOphthalmicSun Pharma Global FZE2014-12-15Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousCardinal Health2011-07-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralPhysicians Total Care, Inc.2001-01-10Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicFalcon Pharmaceuticals, Ltd.2009-11-05Not applicableUs
Ketorolac TromethamineInjection15 mg/mLIntramuscular; IntravenousAGILA SPECIALTIES PRIVATE LIMITED2014-08-05Not applicableUs
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscularCardinal Health2011-07-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralA S Medication Solutions1998-06-17Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscularCardinal Health2000-10-18Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousHospira, Inc.1997-06-05Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-17Not applicableUs
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscularCardinal Health2000-10-18Not applicableUs
Ketorolac TromethamineInjection15 mg/mLIntramuscular; IntravenousWOCKHARDT USA LLC2007-03-27Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousHospira, Inc.1999-01-27Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2014-09-05Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousBd Rx, Inc.2015-11-02Not applicableUs
Ketorolac TromethamineSolution / drops5 mg/mLOphthalmicPreferred Pharmaceuticals Inc.2016-09-07Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralPreferred Pharmaceuticals, Inc.2015-01-21Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicUnit Dose Services2009-11-05Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicSun Pharma Global Inc.2009-11-06Not applicableUs
Ketorolac TromethamineInjection60 mg/2mLIntramuscularAmphastar Pharmaceuticals, Inc.2016-03-11Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicA S Medication Solutions2009-11-06Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscularWest Ward Pharmaceutical Corp.2004-07-21Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscularREMEDYREPACK INC.2013-06-10Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralClinical Solutions Wholesale1998-06-17Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1Oralbryant ranch prepack2010-04-20Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralCentral Texas Community Health Centers1998-06-17Not applicableUs
Ketorolac TromethamineSolution4 mg/mLOphthalmicRebel Distributors Corp2009-11-05Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralProficient Rx LP1998-06-17Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousREMEDYREPACK INC.2016-06-07Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousPfizer Laboratories Div Pfizer Inc2011-05-112016-04-13Us
Ketorolac TromethamineTablet10 mg/1OralREMEDYREPACK INC.2010-12-062016-10-13Us
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousCardinal Health1999-04-26Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicSTAT Rx USA LLC2009-11-05Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousPhysicians Total Care, Inc.2000-11-03Not applicableUs
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscularREMEDYREPACK INC.2014-10-29Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousAGILA SPECIALTIES PRIVATE LIMITED2014-08-05Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousCardinal Health2011-07-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-15Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralA S Medication Solutions2013-05-16Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscularREMEDYREPACK INC.2013-06-122017-11-07Us
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscularHospira, Inc.1997-06-05Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralUnit Dose Services2010-04-20Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralPd Rx Pharmaceuticals, Inc.2010-09-15Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscular; IntravenousWOCKHARDT USA LLC2007-03-27Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousHospira, Inc.1999-01-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralAidarex Pharmaceuticals LLC1998-06-17Not applicableUs
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscularBd Rx, Inc.2015-11-02Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicPreferred Pharmaceuticals, Inc.2015-04-13Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2012-04-10Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicSun Pharma Global Inc.2009-11-06Not applicableUs
Ketorolac TromethamineInjection15 mg/mLIntramuscular; IntravenousAmphastar Pharmaceuticals, Inc.2016-03-11Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralBlenheim Pharmacal, Inc.2011-07-15Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousGeneral Injectables & Vaccines, Inc2012-04-10Not applicableUs
Ketorolac TromethamineSolution / drops5 mg/mLOphthalmicApotex Corp.2009-12-07Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscularMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2010-05-03Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscularREMEDYREPACK INC.2016-03-08Not applicableUs
Ketorolac TromethamineSolution4 mg/mLOphthalmicRebel Distributors Corp2009-11-05Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousFresenius Kabi USA, LLC2001-09-05Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralREMEDYREPACK INC.2016-08-30Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralMylan Pharmaceuticals Inc.2013-05-16Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscularREMEDYREPACK INC.2013-06-142016-10-29Us
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscular; IntravenousCardinal Health1999-04-26Not applicableUs
Ketorolac TromethamineSolution / drops4.5 mg/mLOphthalmicAkorn2014-02-10Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicPhysicians Total Care, Inc.2010-11-03Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscularREMEDYREPACK INC.2015-03-25Not applicableUs
Ketorolac TromethamineInjection60 mg/2mLIntramuscularAGILA SPECIALTIES PRIVATE LIMITED2014-08-05Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscularCardinal Health2001-09-05Not applicableUs
Ketorolac TromethamineSolution / drops5 mg/mLOphthalmicSun Pharma Global FZE2014-12-15Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousA S Medication Solutions2005-04-28Not applicableUs
Ketorolac TromethamineTablet10 mg/1OralRed Pharm Drug, Inc.1998-06-17Not applicableUs
Ketorolac TromethamineInjection15 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.2004-07-21Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralNorthwind Pharmaceuticals, LLC2014-07-15Not applicableUs
Ketorolac TromethamineInjection15 mg/mLIntramuscular; IntravenousWockhardt Limited2007-03-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralCarilion Materials Management1998-06-17Not applicableUs
Ketorolac TromethamineSolution4 mg/mLOphthalmicAkorn Inc.2009-11-05Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2010-04-20Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousBd Rx, Inc.2015-11-02Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2015-04-27Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousCardinal Health2011-07-27Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicSun Pharma Global Inc.2009-11-06Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralAv Kare, Inc.2016-07-25Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralCardinal Health2010-04-20Not applicableUs
Ketorolac TromethamineTablet10 mg/1OralApotheca, Inc2005-10-25Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralH.J. Harkins Company, Inc.2010-04-20Not applicableUs
Ketorolac TromethamineSolution4 mg/mLOphthalmicSandoz Inc2009-11-05Not applicableUs
Ketorolac TromethamineInjection, solution60 mg/2mLIntramuscularCardinal Health2011-07-27Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralReady Meds2013-05-16Not applicableUs
Ketorolac TromethamineTablet, film coated10 mg/1OralA S Medication Solutions1998-06-17Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousSagent Pharmaceuticals2014-09-05Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscularFresenius Kabi USA, LLC2000-10-18Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousPreferred Pharmaceuticals Inc.2016-08-16Not applicableUs
Ketorolac TromethamineInjection, solution15 mg/mLIntramuscular; IntravenousHospira, Inc.1997-06-05Not applicableUs
Ketorolac TromethamineInjection30 mg/mLIntramuscularREMEDYREPACK INC.2013-06-142016-10-29Us
Ketorolac TromethamineSolution / drops5 mg/mLOphthalmicSun Pharma Global FZE2014-12-15Not applicableUs
Ketorolac TromethamineSolution5 mg/mLOphthalmicA S Medication Solutions2009-11-05Not applicableUs
Ketorolac TromethamineTablet10 mg/1OralREMEDYREPACK INC.2011-12-282017-11-09Us
Ketorolac TromethamineTablet, film coated10 mg/1OralRebel Distributors Corp2010-04-20Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscular; IntravenousCardinal Health2011-07-27Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntravenousREMEDYREPACK INC.2015-07-15Not applicableUs
Ketorolac TromethamineInjection, solution30 mg/mLIntramuscularCardinal Health2000-10-18Not applicableUs
Ketotolac TromethamineTablet, film coated10 mg/1OralSTAT Rx USA LLC2010-09-15Not applicableUs
Readysharp KetorolacInjection, solution15 mg/mLIntramuscular; IntravenousTerrain Pharmaceuticals1997-06-05Not applicableUs
Toronova II SuikInjection, solution30 mg/mLIntramuscular; IntravenousAsclemed Usa, Inc.1997-06-05Not applicableUs
Toronova SuikInjection, solution30 mg/mLIntramuscular; IntravenousAsclemed Usa, Inc.1997-06-05Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Toradol Tab 10mgTablet10 mgOralSyntex Inc.1991-12-311996-09-30Canada
Unapproved/Other Products Not Available
International Brands
NameCompany
BedoralBe-Tabs Pharmaceuticals
DoltenPfizer
Dolten SLPfizer
Dorixina forte NFRoemmers
EmodolJayson
EtoracIncepta
KetonicEskayef
KetoraMedicon
LixidolRoche
SyndolRoche
TaradylRoche
TarasynRoche
ToradolRoche
Brand mixtures
NameLabellerIngredients
OmidriaOmeros Corporation
Salts
Name/CASStructureProperties
Ketorolac tromethamine
74103-07-4
Thumb
  • InChI Key: BWHLPLXXIDYSNW-UHFFFAOYSA-N
  • Monoisotopic Mass: 376.163436501
  • Average Mass: 376.409
DBSALT001045
Categories
UNIIYZI5105V0L
CAS number74103-06-3
WeightAverage: 255.2686
Monoisotopic: 255.089543287
Chemical FormulaC15H13NO3
InChI KeyOZWKMVRBQXNZKK-UHFFFAOYSA-N
InChI
InChI=1S/C15H13NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13/h1-7,11H,8-9H2,(H,18,19)
IUPAC Name
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid
SMILES
OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1
Pharmacology
IndicationFor the short-term (~5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.
Structured Indications
PharmacodynamicsKetorolac, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. It is a peripherally acting analgesic. The biological activity of ketorolac tromethamine is associated with the S-form. Ketorolac tromethamine possesses no sedative or anxiolytic properties.
Mechanism of actionKetorolac is a nonsteroidal anti-inflammatory drug (NSAID) chemically related to indomethacin and tolmetin. Ketorolac tromethamine is a racemic mixture of [-]S- and [+]R-enantiomeric forms, with the S-form having analgesic activity. Its antiinflammatory effects are believed to be due to inhibition of both cylooxygenase-1 (COX-1) and cylooxygenase-2 (COX-2) which leads to the inhibition of prostaglandin synthesis leading to decreased formation of precursors of prostaglandins and thromboxanes from arachidonic acid. The resultant reduction in prostaglandin synthesis and activity may be at least partially responsible for many of the adverse, as well as the therapeutic, effects of these medications. Analgesia is probably produced via a peripheral action in which blockade of pain impulse generation results from decreased prostaglandin activity. However, inhibition of the synthesis or actions of other substances that sensitize pain receptors to mechanical or chemical stimulation may also contribute to the analgesic effect. In terms of the ophthalmic applications of ketorolac - ocular administration of ketorolac reduces prostaglandin E2 levels in aqueous humor, secondary to inhibition of prostaglandin biosynthesis.
TargetKindPharmacological actionActionsOrganismUniProt ID
Prostaglandin G/H synthase 2Proteinyes
inhibitor
HumanP35354 details
Prostaglandin G/H synthase 1Proteinunknown
inhibitor
HumanP23219 details
Related Articles
AbsorptionRapidly and completely absorbed after oral administration
Volume of distribution
  • 0.26 ± 0.08 L/kg [children 4 to 8 years old]
Protein binding99%
Metabolism

Primarily hepatic. Less than 50% of a dose is metabolized. The major metabolites are a glucuronide conjugate, which may also be formed in the kidney, and p-hydroxy ketorolac. Neither metabolite has significant analgesic activity.

SubstrateEnzymesProduct
Ketorolac
Not Available
4-hydroxy ketorolacDetails
Route of eliminationThe principal route of elimination of ketorolac and its metabolites is renal. Approximately 6% of a dose is excreted in the feces.
Half life2.5 hours for the S-enantiomer compared with 5 hours for the R-enantiomer
Clearance
  • 0.042 +/- 0.01 L/hr/kg [Pediatric Patients]
  • 0.02 L/h/kg [Normal Subjects IM]
  • 0.03 L/h/kg [Normal Subjects oral]
  • 0.02 L/h/kg [Healthy Elderly Subjects IM]
  • 0.02 L/h/kg [Healthy Elderly Subjects oral]
  • 0.03 L/h/kg [Patients with Hepatic Dysfunction IM]
  • 0.03 L/h/kg [Patients with Hepatic Dysfunction oral]
  • 0.02 L/h/kg [Patients with Renal Impairment IM]
  • 0.02 L/h/kg [Patients with Renal Impairment oral]
  • 0.02 L/h/kg [Renal Dialysis Patients IM]
ToxicityLD50 = 189 mg/kg (rat, oral).
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Ketorolac Action PathwayDrug actionSMP00098
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Ketorolac is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Ketorolac is combined with 19-norandrostenedione.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when Ketorolac is combined with 4-Androstenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Ketorolac is combined with 5-androstenedione.Experimental, Illicit
AbciximabKetorolac may increase the anticoagulant activities of Abciximab.Approved
AcebutololKetorolac may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Aceclofenac.Approved
AcenocoumarolKetorolac may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Acetovanillone.Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinKetorolac may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Adapalene.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Aldosterone.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.Approved
AliskirenKetorolac may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlprenololKetorolac may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Ketorolac.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Amcinonide.Approved
AmikacinKetorolac may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideKetorolac may decrease the antihypertensive activities of Amiloride.Approved
AmrubicinKetorolac may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodKetorolac may increase the anticoagulant activities of Ancrod.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Ketorolac is combined with Anecortave.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Anisodamine.Investigational
annamycinKetorolac may decrease the excretion rate of annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Antipyrine.Approved
Antithrombin III humanKetorolac may increase the anticoagulant activities of Antithrombin III human.Approved
Aop200704Ketorolac may decrease the antihypertensive activities of Aop200704.Investigational
ApixabanKetorolac may increase the anticoagulant activities of Apixaban.Approved
ApramycinKetorolac may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Ketorolac is combined with Apremilast.Approved, Investigational
ArbekacinKetorolac may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved
ArdeparinKetorolac may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanKetorolac may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololKetorolac may decrease the antihypertensive activities of Arotinolol.Approved
AtenololKetorolac may decrease the antihypertensive activities of Atenolol.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Atracurium besylate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ketorolac.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Balsalazide.Approved, Investigational
BalsalazideKetorolac may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminKetorolac may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Beclomethasone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololKetorolac may decrease the antihypertensive activities of Befunolol.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Ketorolac.Approved, Investigational
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ketorolac.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Benoxaprofen.Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ketorolac.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Betamethasone.Approved, Vet Approved
BetaxololKetorolac may decrease the antihypertensive activities of Betaxolol.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Betulinic Acid.Investigational
BevantololKetorolac may decrease the antihypertensive activities of Bevantolol.Approved
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ketorolac.Approved, Investigational
BisoprololKetorolac may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinKetorolac may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololKetorolac may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Bucillamine.Investigational
BucindololKetorolac may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Budesonide.Approved
BufuralolKetorolac may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumetanideKetorolac may decrease the diuretic activities of Bumetanide.Approved
BupranololKetorolac may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Ketorolac.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Ketorolac.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Ketorolac.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ketorolac.Approved
CarprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololKetorolac may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolKetorolac may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Celecoxib.Approved, Investigational
CeliprololKetorolac may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinKetorolac may increase the anticoagulant activities of Certoparin.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ketorolac.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Ketorolac.Approved
CinoxacinKetorolac may increase the neuroexcitatory activities of Cinoxacin.Approved, Withdrawn
CiprofloxacinKetorolac may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
Citric AcidKetorolac may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clobetasol propionate.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clocortolone.Approved
ClodronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clodronate.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ketorolac.Vet Approved
ColesevelamColesevelam can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ketorolac resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Cortisone acetate.Approved
CurcuminThe risk or severity of adverse effects can be increased when Ketorolac is combined with Curcumin.Investigational
CyclosporineKetorolac may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
D-LimoneneThe risk or severity of adverse effects can be increased when Ketorolac is combined with D-Limonene.Investigational
Dabigatran etexilateKetorolac may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinKetorolac may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidKetorolac may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DaunorubicinKetorolac may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe risk or severity of adverse effects can be increased when Ketorolac is combined with Deferasirox.Approved, Investigational
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when Ketorolac is combined with dehydroepiandrosterone sulfate.Investigational
DesirudinKetorolac may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desmopressin.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ketorolac.Approved
DextranKetorolac may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Ketorolac may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ketorolac may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ketorolac may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Diclofenac.Approved, Vet Approved
DicoumarolKetorolac may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Ketorolac is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Difluocortolone.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ketorolac.Approved
DihydrostreptomycinKetorolac may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Ketorolac.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ketorolac.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ketorolac.Approved
DoxorubicinKetorolac may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneKetorolac may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Droxicam.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Duvelisib.Investigational
E6201The risk or severity of adverse effects can be increased when Ketorolac is combined with E6201.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ebselen.Investigational
Edetic AcidKetorolac may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanKetorolac may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Ketorolac.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Ketorolac.Approved
EnoxacinKetorolac may increase the neuroexcitatory activities of Enoxacin.Approved
EnoxaparinKetorolac may increase the anticoagulant activities of Enoxaparin.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Ketorolac is combined with Epirizole.Approved
EpirubicinKetorolac may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneKetorolac may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketorolac.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Ketorolac.Approved
EquileninThe risk or severity of adverse effects can be increased when Ketorolac is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Equilin.Approved
EsmololKetorolac may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Estrone sulfate.Approved
Etacrynic acidKetorolac may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etanercept.Approved, Investigational
Ethyl biscoumacetateKetorolac may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etofenamate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Ketorolac is combined with Evening primrose oil.Approved
exisulindThe risk or severity of adverse effects can be increased when Ketorolac is combined with exisulind.Investigational
FenbufenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ketorolac.Vet Approved
FleroxacinKetorolac may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ketorolac.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when Ketorolac is combined with fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fludrocortisone.Approved
FluindioneKetorolac may increase the anticoagulant activities of Fluindione.Investigational
FlumequineKetorolac may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flunixin.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ketorolac.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Flurbiprofen.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone furoate.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Fluticasone Propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ketorolac.Approved, Nutraceutical, Vet Approved
FondaparinuxKetorolac may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumKetorolac may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ketorolac.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Ketorolac.Approved
FramycetinKetorolac may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideKetorolac may decrease the diuretic activities of Furosemide.Approved, Vet Approved
GabexateKetorolac may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinKetorolac may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinKetorolac may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Ketorolac.Approved, Withdrawn
GemifloxacinKetorolac may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinKetorolac may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinKetorolac may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AKetorolac may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GrepafloxacinKetorolac may increase the neuroexcitatory activities of Grepafloxacin.Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Ketorolac is combined with HE3286.Investigational
HeparinKetorolac may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Higenamine.Investigational
HirulogKetorolac may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004The risk or severity of adverse effects can be increased when Ketorolac is combined with HMPL-004.Investigational
HydralazineKetorolac may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ketorolac.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ketorolac.Approved
Hygromycin BKetorolac may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Ketorolac is combined with Icatibant.Approved
IdarubicinKetorolac may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
idraparinuxKetorolac may increase the anticoagulant activities of idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketorolac.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Ketorolac.Investigational
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ketorolac.Approved
IndenololKetorolac may decrease the antihypertensive activities of Indenolol.Withdrawn
IndomethacinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Indoprofen.Withdrawn
INNO-206Ketorolac may decrease the excretion rate of INNO-206 which could result in a higher serum level.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Ketorolac.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Ketorolac is combined with Istaroxime.Investigational
KanamycinKetorolac may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ketoprofen.Approved, Vet Approved
LabetalolKetorolac may decrease the antihypertensive activities of Labetalol.Approved
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ketorolac.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Leflunomide.Approved, Investigational
LepirudinKetorolac may increase the anticoagulant activities of Lepirudin.Approved
LevobunololKetorolac may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinKetorolac may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Ketorolac.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Ketorolac.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Ketorolac.Approved
LomefloxacinKetorolac may increase the neuroexcitatory activities of Lomefloxacin.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Ketorolac.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Loxoprofen.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ketorolac.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Ketorolac.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Masoprocol.Approved
ME-609The risk or severity of adverse effects can be increased when Ketorolac is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mefenamic acid.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mesalazine.Approved
MesalazineKetorolac may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Ketorolac is combined with Metamizole.Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ketorolac.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ketorolac.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Methylprednisolone.Approved, Vet Approved
MetipranololKetorolac may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ketorolac.Approved
MetoprololKetorolac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideKetorolac may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ketorolac.Approved
MivacuriumThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mivacurium.Approved
MizoribineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Ketorolac.Approved
MometasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ketorolac.Approved
MoxifloxacinKetorolac may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nabumetone.Approved
NadololKetorolac may decrease the antihypertensive activities of Nadolol.Approved
NadroparinKetorolac may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nafamostat.Investigational
NafamostatKetorolac may increase the anticoagulant activities of Nafamostat.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Naftifine.Approved
Nalidixic AcidKetorolac may increase the neuroexcitatory activities of Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Ketorolac is combined with NCX 1022.Investigational
NCX 4016The risk or severity of adverse effects can be increased when Ketorolac is combined with NCX 4016.Investigational
NeamineKetorolac may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NemonoxacinKetorolac may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinKetorolac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nepafenac.Approved
NetilmicinKetorolac may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Niflumic Acid.Approved
NimesulideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nimesulide.Approved, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Nitroaspirin.Investigational
NorfloxacinKetorolac may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinKetorolac may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oleoyl estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Ketorolac.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olsalazine.Approved
OlsalazineKetorolac may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Ketorolac.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Orgotein.Vet Approved
OtamixabanKetorolac may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxaprozin.Approved
OxprenololKetorolac may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Oxyphenbutazone.Withdrawn
PamidronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Parecoxib.Approved
ParomomycinKetorolac may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
PazufloxacinKetorolac may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinKetorolac may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololKetorolac may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentosan PolysulfateKetorolac may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pentoxifylline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketorolac.Approved
PhenindioneKetorolac may increase the anticoagulant activities of Phenindione.Approved
PhenprocoumonKetorolac may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pimecrolimus.Approved, Investigational
PindololKetorolac may decrease the antihypertensive activities of Pindolol.Approved
PirarubicinKetorolac may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideKetorolac may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pirfenidone.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Piroxicam.Approved, Investigational
PlicamycinKetorolac may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ketorolac.Approved
PractololKetorolac may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Ketorolac.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prasterone.Approved, Nutraceutical
PrednicarbateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pregnenolone.Experimental
ProbenecidThe serum concentration of Ketorolac can be increased when it is combined with Probenecid.Approved
PropacetamolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Propacetamol.Approved
PropranololKetorolac may decrease the antihypertensive activities of Propranolol.Approved, Investigational
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ketorolac.Experimental
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Ketorolac.Experimental, Investigational
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ketorolac.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Ketorolac.Vet Approved
Protein CKetorolac may increase the anticoagulant activities of Protein C.Approved
Protein S humanKetorolac may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeKetorolac may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinKetorolac may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Ketorolac is combined with PTC299.Investigational
PuromycinKetorolac may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Ketorolac.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ketorolac.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Ketorolac.Approved
RapacuroniumThe risk or severity of adverse effects can be increased when Ketorolac is combined with Rapacuronium.Withdrawn
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Ketorolac.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Resveratrol.Experimental, Investigational
ReviparinKetorolac may increase the anticoagulant activities of Reviparin.Approved
RibostamycinKetorolac may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Risedronate.Approved, Investigational
RivaroxabanKetorolac may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Rofecoxib.Investigational, Withdrawn
RosoxacinKetorolac may increase the neuroexcitatory activities of Rosoxacin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Ketorolac.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Ketorolac.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ketorolac.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Ketorolac is combined with Seratrodast.Approved, Investigational
SisomicinKetorolac may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SotalolKetorolac may decrease the antihypertensive activities of Sotalol.Approved
SP1049CKetorolac may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinKetorolac may increase the neuroexcitatory activities of Sparfloxacin.Approved
SpectinomycinKetorolac may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Ketorolac.Approved
SpironolactoneKetorolac may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Ketorolac is combined with SRT501.Investigational
StreptomycinKetorolac may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinKetorolac may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulfasalazine.Approved
SulfasalazineKetorolac may increase the nephrotoxic activities of Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Sulindac.Approved
SulodexideKetorolac may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Ketorolac.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Suprofen.Approved, Withdrawn
TacrolimusKetorolac may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Ketorolac.Approved
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Ketorolac.Approved
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ketorolac.Approved
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Technetium tc 99m etidronate.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Technetium Tc-99m Medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Ketorolac.Approved, Investigational
TemafloxacinKetorolac may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Ketorolac.Experimental, Investigational
TenofovirThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Ketorolac is combined with Teriflunomide.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tiaprofenic acid.Approved
TiludronateThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tiludronate.Approved, Vet Approved
TimololKetorolac may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tixocortol.Approved
TobramycinKetorolac may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tolmetin.Approved
TorasemideKetorolac may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Ketorolac.Approved
TranilastThe risk or severity of adverse effects can be increased when Ketorolac is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ketorolac.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ketorolac.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Ketorolac is combined with Triamcinolone.Approved, Vet Approved
TriamtereneKetorolac may decrease the antihypertensive activities of Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ketorolac.Approved, Vet Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Ketorolac is combined with Trisalicylate-choline.Approved
TrovafloxacinKetorolac may increase the neuroexcitatory activities of Trovafloxacin.Approved, Withdrawn
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ketorolac.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Ketorolac is combined with Valdecoxib.Investigational, Withdrawn
ValrubicinKetorolac may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Ketorolac.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Ketorolac.Approved
WarfarinKetorolac may increase the anticoagulant activities of Warfarin.Approved
XimelagatranKetorolac may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Ketorolac may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zaltoprofen.Approved
ZileutonThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zileuton.Approved, Investigational, Withdrawn
Zoledronic acidThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Ketorolac is combined with Zomepirac.Withdrawn
ZorubicinKetorolac may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
  • Take with food to reduce GI irritation
References
Synthesis Reference

Peter J. Harrington, Hiralal N. Khatri, George C. Schloemer, “Preparation of ketorolac.” U.S. Patent US6323344, issued October, 1989.

US6323344
General ReferencesNot Available
External Links
ATC CodesM01AB15S01BC05
AHFS Codes
  • 28:08.04.92
  • 52:08.20
PDB EntriesNot Available
FDA labelDownload (138 KB)
MSDSDownload (76.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9919
Blood Brain Barrier+0.7918
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.7127
P-glycoprotein inhibitor INon-inhibitor0.9624
P-glycoprotein inhibitor IINon-inhibitor0.8684
Renal organic cation transporterNon-inhibitor0.6042
CYP450 2C9 substrateNon-substrate0.7845
CYP450 2D6 substrateNon-substrate0.7046
CYP450 3A4 substrateNon-substrate0.6338
CYP450 1A2 substrateInhibitor0.5483
CYP450 2C9 inhibitorNon-inhibitor0.9081
CYP450 2D6 inhibitorNon-inhibitor0.9333
CYP450 2C19 inhibitorNon-inhibitor0.9225
CYP450 3A4 inhibitorNon-inhibitor0.9621
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9467
Ames testNon AMES toxic0.7615
CarcinogenicityNon-carcinogens0.9592
BiodegradationNot ready biodegradable0.5254
Rat acute toxicity2.5902 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9478
hERG inhibition (predictor II)Non-inhibitor0.9298
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn strides llc
  • Amphastar pharmaceutical inc
  • Apotex inc richmond hill
  • Apothecon inc div bristol myers squibb
  • App pharmaceuticals llc
  • Baxter healthcare corp anesthesia and critical care
  • Baxter healthcare corp anesthesia critical care
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Gland pharma ltd
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Sandoz canada inc
  • Sun pharma global inc
  • Wockhardt ltd
  • Roche palo alto llc
  • Allergan inc
  • Allergan
  • Akorn inc
  • Alcon inc
  • Roxro pharma inc
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Roxane laboratories inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Solution / dropsOphthalmic5 mg/mL
SolutionOphthalmic0.5 %
SolutionOphthalmic0.4 %
SolutionOphthalmic0.45 %
Solution / dropsOphthalmic4.5 mg/mL
SolutionIntramuscular30 mg
TabletOral10 mg
InjectionIntramuscular30 mg/mL
InjectionIntramuscular60 mg/2mL
InjectionIntramuscular; Intravenous15 mg/mL
InjectionIntramuscular; Intravenous30 mg/mL
Injection, solutionIntramuscular15 mg/mL
Injection, solutionIntramuscular30 mg/mL
Injection, solutionIntramuscular60 mg/2mL
Injection, solutionIntramuscular; Intravenous15 mg/mL
Injection, solutionIntramuscular; Intravenous30 mg/mL
Injection, solutionIntramuscular; Intravenous60 mg/2mL
Injection, solutionIntravenous30 mg/mL
SolutionOphthalmic4 mg/mL
SolutionOphthalmic5 mg/1
SolutionOphthalmic5 mg/mL
Solution / dropsOphthalmic4 mg/mL
TabletOral10 mg/1
Tablet, film coatedOral10 mg/1
LiquidIntramuscular30 mg
Injection, solution, concentrateIntraocular
Spray, meteredNasal15.75 mg/1
SolutionIntramuscular10 mg
LiquidIntramuscular10 mg
Prices
Unit descriptionCostUnit
Acular 0.5% Solution 10ml Bottle254.39USD bottle
Acular 0.5% Solution 5ml Bottle122.36USD bottle
Ketorolac Tromethamine 0.4% Solution 5ml Bottle109.72USD bottle
Ketorolac tromethamine powder71.05USD g
Acular 0.5% Solution 3ml Bottle59.34USD bottle
Acular ls 0.4% ophth sol24.46USD ml
Acular 0.5% eye drops18.68USD ml
Ketorolac 30 mg/ml syringe8.77USD ml
Ketorolac 15 mg/ml syringe8.39USD ml
Acuvail 0.45% ophth solution4.17USD each
Ketorolac Tromethamine 30 mg/ml3.9USD ml
Acular 0.5 % Solution3.78USD ml
Toradol 10 mg/ml2.52USD ml
Ketorolac im 30 mg/ml syring2.11USD ml
Apo-Ketorolac 0.5 % Solution2.11USD ml
Ratio-Ketorolac 0.5 % Solution2.11USD ml
Toradol 10 mg tablet1.53USD tablet
Ketorolac Tromethamine 10 mg tablet1.06USD tablet
Ketorolac 10 mg tablet0.93USD tablet
Toradol 10 mg Tablet0.76USD tablet
Apo-Ketorolac 10 mg Tablet0.43USD tablet
Novo-Ketorolac 10 mg Tablet0.43USD tablet
Nu-Ketorolac 10 mg Tablet0.43USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1328614 No1994-04-192011-04-19Canada
US5110493 No1992-11-052009-11-05Us
US6333044 No1998-12-252018-12-25Us
US7842714 No2009-08-152029-08-15Us
US8008338 Yes2007-11-242027-11-24Us
US8173707 No2003-07-302023-07-30Us
US8207215 Yes2004-11-282024-11-28Us
US8377982 Yes2004-11-282024-11-28Us
US8512717 No2008-03-072028-03-07Us
US8541463 Yes2004-11-282024-11-28Us
US8586633 No2003-07-302023-07-30Us
US8648107 No2004-05-282024-05-28Us
US8906950 No2004-05-282024-05-28Us
US8946281 No2004-05-282024-05-28Us
US8992952 No2004-08-052024-08-05Us
US9066856 No2013-10-232033-10-23Us
US9192571 No2008-03-072028-03-07Us
US9216127 No2004-05-282024-05-28Us
US9216167 No2004-05-282024-05-28Us
US9278101 No2003-07-302023-07-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point165-167 °C (tromethamine salt)Not Available
water solubility25 mg/mL (tromethamine salt)Not Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.513 mg/mLALOGPS
logP2.66ALOGPS
logP2.28ChemAxon
logS-2.7ALOGPS
pKa (Strongest Acidic)3.84ChemAxon
pKa (Strongest Basic)-7.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area59.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity70.19 m3·mol-1ChemAxon
Polarizability26.67 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as acetophenones. These are organic compounds containing the acetophenone structure.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAcetophenones
Direct ParentAcetophenones
Alternative Parents
Substituents
  • Acetophenone
  • Aryl ketone
  • Pyrrolizine
  • Benzoyl
  • Substituted pyrrole
  • Heteroaromatic compound
  • Pyrrole
  • Ketone
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Hocherl K, Kammerl MC, Schumacher K, Endemann D, Grobecker HF, Kurtz A: Role of prostanoids in regulation of the renin-angiotensin-aldosterone system by salt intake. Am J Physiol Renal Physiol. 2002 Aug;283(2):F294-301. [PubMed:12110513 ]
  2. Blais V, Zhang J, Rivest S: In altering the release of glucocorticoids, ketorolac exacerbates the effects of systemic immune stimuli on expression of proinflammatory genes in the brain. Endocrinology. 2002 Dec;143(12):4820-7. [PubMed:12446609 ]
  3. Ma W, Eisenach JC: Intraplantar injection of a cyclooxygenase inhibitor ketorolac reduces immunoreactivities of substance P, calcitonin gene-related peptide, and dynorphin in the dorsal horn of rats with nerve injury or inflammation. Neuroscience. 2003;121(3):681-90. [PubMed:14568028 ]
  4. Ma W, Eisenach JC: Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience. 2003;121(3):691-704. [PubMed:14568029 ]
  5. Padi SS, Jain NK, Singh S, Kulkarni SK: Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor. Eur J Pharmacol. 2004 Apr 26;491(1):69-76. [PubMed:15102535 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Bosch-Marce M, Claria J, Titos E, Masferrer JL, Altuna R, Poo JL, Jimenez W, Arroyo V, Rivera F, Rodes J: Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology. 1999 May;116(5):1167-75. [PubMed:10220509 ]
  2. Lashbrook JM, Ossipov MH, Hunter JC, Raffa RB, Tallarida RJ, Porreca F: Synergistic antiallodynic effects of spinal morphine with ketorolac and selective COX1- and COX2-inhibitors in nerve-injured rats. Pain. 1999 Jul;82(1):65-72. [PubMed:10422661 ]
  3. Dionne RA, Khan AA, Gordon SM: Analgesia and COX-2 inhibition. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S63-70. [PubMed:11695255 ]
  4. Uzan A: The unexpected side effects of new nonsteroidal anti-inflammatory drugs. Expert Opin Emerg Drugs. 2005 Nov;10(4):687-8. [PubMed:16262557 ]
  5. Blais V, Turrin NP, Rivest S: Cyclooxygenase 2 (COX-2) inhibition increases the inflammatory response in the brain during systemic immune stimuli. J Neurochem. 2005 Dec;95(6):1563-74. Epub 2005 Nov 8. [PubMed:16277613 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 03:58